Milder weather, retailer destocking and increased private label competition have all been cited by hygiene and health products maker Reckitt Benckiser as factors contributing to a 9% dip in its Over-The-Counter (OTC) division in the first quarter.
The division includes brands such as Nurofen and Gaviscon, as well as chest congestion brand Mucinex, the latter of which experienced share loss due to 'private label competition' in its category, the group said.
Sales in the OTC division stood at £470 million for the quarter.
